Search results
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks· 13 hours agoFree Report) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which Pfizer falls in, has ...
2 Dividend Stocks Billionaires Are Buying: Should You?
Motley Fool via Yahoo Finance· 3 days agoPfizer Pfizer hasn't performed well recently. Despite its important role in developing effective...
Why Things Could Get Worse for Pfizer Stock Before They Get Better
Motley Fool via Yahoo Finance· 5 days agoThis new round of cuts will result in Pfizer incurring one-time charges totaling $1.7 billion, the...
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
Motley Fool via Yahoo Finance· 2 days agoThe dividend isn't the only thing attractive about this stock Keith Speights (Pfizer): Income...
Moderna's combo Covid, flu vaccine meets goals in late-stage study - Boston Business Journal
The Business Journals· 2 hours agoModerna Inc. is making steady headway on its plan to launch all four products from its respiratory...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 3 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
FDA Gives Nod to RSV Vaccine for People in Their 50s
US News & World Report· 5 hours agoDrugmaker GSK's Arexvy vaccine, as well as vaccines from Pfizer and Moderna, are already approved for use in adults 60 and older, since age brings higher ...
2 High-Yield Dividend Stocks to Buy Right Now | The Motley Fool
The Motley Fool· 5 days agoDividend stocks are sensitive to interest rates. When rates fall, studies show that money managers...
Moderna’s flu-COVID combo shot hits goal in late-stage trial
Detroit News· 3 hours agoModerna Inc. said its combination flu and COVID shot met the goals of a pivotal late-stage trial,...
FDA approves first RSV vaccine for at-risk adults in their 50s
CBS News· 3 days agoGlobal vaccine and drugmaker GSK asked the FDA in February to expand approval beyond adults 60 and...